Investor Overview

Webcast ImageWebcast
AtriCure, Inc. at JMP Securities Life Science Conference (Replay)
06/20/17 at 3:30 p.m. ET
Webcast ImageWebcast
Q1 2017 AtriCure, Inc. Earnings Conference Call (Replay)
05/04/17 at 4:30 p.m. ET

Corporate Profile

AtriCure is a medical device company providing innovative solutions designed to decrease the global Afib epidemic.

Stock Quote

ATRC (Common)
PriceChange% ChangeVolume
$23.91 + 0.582.49%424,346
Previous CloseToday's OpenIntraday HighIntraday Low
$23.33$23.33$23.94$23.11
Exchange: NASDAQ (US Dollar)
06/23/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Reports

Date
06/19/17
Download Documentation Investor Presentation
04/18/17
Download Documentation 2016 Annual Report

All Recent News

DateTitle 
05/18/17AtriCure to Present at the JMP Securities Life Science Conference
MASON, Ohio--(BUSINESS WIRE)--May 18, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the JMP Securities Life Science Conference at the St. Regis Hotel in New York City on Tuesday, June 20, 2017. Management is scheduled to present at 3:30 p.m. Eastern Time. A live audio webcast of the presentati... 
Printer Friendly Version
05/04/17AtriCure Reports First Quarter 2017 Financial Results
Worldwide revenue of $41.3 million – an increase of 14.8% year over year U.S. revenue of $33.3 million – an increase of 17.7% year over year International revenue of $8.0 million – an increase 4.4% year over year MASON, Ohio--(BUSINESS WIRE)--May 4, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) managemen... 
Printer Friendly Version
04/25/17AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio--(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, which makes it the most widely used of all d... 
Printer Friendly Version
04/07/17AtriCure to Announce First Quarter 2017 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Apr. 7, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2017 financial results on Thursday, May 4, 2017. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 4, 2017 to discuss its first quarter 2017 financial results.... 
Printer Friendly Version
  More News >>

National Recent News

DateTitle 
05/18/17AtriCure to Present at the JMP Securities Life Science Conference
MASON, Ohio--(BUSINESS WIRE)--May 18, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the JMP Securities Life Science Conference at the St. Regis Hotel in New York City on Tuesday, June 20, 2017. Management is scheduled to present at 3:30 p.m. Eastern Time. A live audio webcast of the presentati... 
Printer Friendly Version
05/04/17AtriCure Reports First Quarter 2017 Financial Results
Worldwide revenue of $41.3 million – an increase of 14.8% year over year U.S. revenue of $33.3 million – an increase of 17.7% year over year International revenue of $8.0 million – an increase 4.4% year over year MASON, Ohio--(BUSINESS WIRE)--May 4, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) managemen... 
Printer Friendly Version
04/07/17AtriCure to Announce First Quarter 2017 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Apr. 7, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2017 financial results on Thursday, May 4, 2017. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, May 4, 2017 to discuss its first quarter 2017 financial results.... 
Printer Friendly Version
03/21/17AtriCure Names Two New Members to its Board of Directors
MASON, Ohio--(BUSINESS WIRE)--Mar. 21, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that Regina Groves and B. Kristine Johnson have been appointed to its Board of Directors. In addition, the company announced that Michael Hooven and Karen Robards, two existing members of the Board of Directors, will not stand for re-elect... 
Printer Friendly Version
  More National News >>

International Recent News

DateTitle 
04/25/17AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management MASON, Ohio--(BUSINESS WIRE)--Apr. 25, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 100,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, which makes it the most widely used of all d... 
Printer Friendly Version
03/14/17AtriCure Names National Principal Investigator for the CONVERGE IDE Clinical Trial
MASON, Ohio--(BUSINESS WIRE)--Mar. 14, 2017-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has named Dr. David B. DeLurgio as the national principal investigator (PI) for the CONVERGE IDE clinical trial. Dr. DeLurgio is a cardiac electrophysiologist at Emory Healthcare in Atlanta, GA. He is Director of Electrophysiology... 
Printer Friendly Version
11/01/16AtriCure Announces Approval for the cryoICE™ Platform in Japan
Approval adds to the growing portfolio of AtriCure products now available in the Japanese market MASON, Ohio--(BUSINESS WIRE)--Nov. 1, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for its cryoICE™ platform and CRYO2 cryoablation ... 
Printer Friendly Version
06/29/16AtriCure Receives CE Mark for the AtriClip® PRO2 Device
CE Mark brings the increased functionality of the AtriClip PRO2 device to the European market for use in managing the left atrial appendage; product was launched in the U.S. in April 2016 MASON, Ohio--(BUSINESS WIRE)--Jun. 29, 2016-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it has received CE Mark for the AtriClip PRO2 Left ... 
Printer Friendly Version
  More International News >>

Company Calendar

There are currently no events scheduled.
  More Events >>

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.